Skip to content

Vitamin D Supplementation for Severe Pneumonia in Under-five Children

Vitamin D Supplementation for Severe Pneumonia in Under-five Children: A Double Blind, Randomized Placebo Controlled Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/01/003317
Enrollment
324
Registered
2013-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- pneumonia Health Condition 2: J189- Pneumonia, unspecified organism

Interventions

Intervention1: vitamin D: Single oral dose of 100,000 IU at enrolment Control Intervention1: Placebo: Identically colored and packaged inert powder single dose at enrolment Control Intervention2: Plac

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with severe pneumonia

Exclusion criteria

Exclusion criteria: Exclusion criteria 1. Children who have received vitamin D or calcium supplements within last 4 weeks, as ascertained on verbal enquiry (ingestion of oral formulation as sachets/granules or syrups or tablets). Where ever possible the parents will be asked to show the prescription of the physician or empty bottles, sachets or tablets consumed by the child. 2. Children with clinical features of rickets 3. Children with severe malnutrition (weight for height less than -3 SD of WHO standards or presence of bipedal edema) 4. Known asthmatics 5. Those with complicated pneumonia (lung abscess, pleural effusion, empyema) or illness severe enough to require ventilation. 6. Those suffering from any chronic respiratory disease including respiratory tract malformations and chest wall deformities, heart disease (congenital/acquired), renal or hepatic insufficiency, neurological illness resulting in abnormalities of muscle tone/power 7. Those known to have hypercalcemia or allergy to vitamin D 8. Children immunized with pneumococcal/flu vaccine 9. Known immunodeficiency

Design outcomes

Primary

MeasureTime frame
1. Time to resolution of severe pneumonia: The duration from the enrolment till the chest indrawing is no longer present, and continue to be absent for next 24 hours. 2. Proportion of children having a repeat episode of pneumonia in next six months. Timepoint: 1. 7 days 2. 6 months

Secondary

MeasureTime frame
Change in serum levels of cathelicidinTimepoint: 72 hours;Change in serum levels of immunoglobulins (Ig A, IgG, IgM)Timepoint: 72 hours;Duration of hospitalizationTimepoint: At discharge;Failure rate (Non-response after 48 hours of antibiotic therapy)Timepoint: 48 hours;Fever clearance timeTimepoint: 7 days;Time to complete recovery from pneumonia (Normalization of RR)Timepoint: 7 days;Time to start oral feedsTimepoint: 7 days

Countries

India

Contacts

Public ContactPiyush Gupta

University College of Medical Sciences

prof.piyush.gupta@gmail.com9811597172

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026